Researchers in the United Kingdom have discovered that INSL3, a hormone that develops in men during puberty, could be used to predict certain age-related diseases, including bone weakness, sexual dysfunction, diabetes, and cardiovascular disease.  

INSL3 is made by the same cells in the testes that make testosterone. However, unlike testosterone, which fluctuates throughout a man’s life, INSL3 remains consistent, with the level at puberty remaining largely the same throughout a man’s life before dipping slightly in old age.  

This makes the University of Nottingham discovery the first clear and reliable predictive biomarker of age-related morbidity. This opens up exciting possibilities for predicting age-related illnesses and finding ways to prevent the onset of these diseases with early intervention.

“The holy grail of aging research is to reduce the fitness gap that appears as people age,” says Professor Ravinder Anand-Ivell. “Understanding why some people are more likely to develop disability and disease as they age is vital so that interventions can be found to ensure people not only live a long life but also a healthy life as they age. Our hormone discovery is an important step in understanding this and will pave the way for not only helping people individually but also helping to ease the care crisis we face as a society.”

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

The team analyzed blood samples from 3,000 men from 8 regional centers in north, south, east, and west of Europe, including the UK, with two samples taken four years apart. The results showed that unlike testosterone, INSL3 remains at consistent levels in individuals. For practical, clinical purposes, a man with high INSL3 when young will still have relatively high INSL3 when he is older, but someone with low INSL3 already at a young age, will have low INSL3 when older, making him more likely to acquire typical age-related illnesses.

The study also showed that the normal male population, even when young and relatively healthy, still shows a wide variation between individuals in the concentration of INSL3 in the blood—almost 10-fold.

 “Now we know the important role this hormone plays in predicting disease and how it varies amongst men we are turning our attention to finding out what factors have the most influence on the level of INSL3 in the blood,” says coauthor Professor Richard Ivell. “Preliminary work suggests early life nutrition may play a role, but many other factors such as genetics or exposure to some environmental endocrine disruptors may play a part.”

The findings were published recently in Frontiers in Endocrinology.